Clinical Trials Currently Enrolling at Banner Alzheimer's Institute

Clinical trials are key to advancing the health care landscape and how we treat illnesses. Banner Alzheimer’s Institute (BAI) is proud to offer research studies to patients and people in the community. Studies here are focused on Alzheimer’s disease and other dementias. There are ways you can help research whether you have memory loss or not

Below is a list of some of our ongoing clinical trials at Banner Alzheimer's Institute in both Phoenix and Tucson, Ariz.

Phoenix, Ariz.

Studies for Participants Without Memory Loss

• GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype (NCT02564692) Learn more at GeneMatch. 
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (NCT04468659)

Studies for Participants With and Without Memory Loss

• Alzheimer’s Disease Research Center (ADRC) (NCT01421420)
• TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD) (NCT04004767)
• Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (NCT02854033)
• Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) (NCT05617014)

Studies for Participants With Memory Loss

• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (NCT04241068)
• A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2) (NCT04592874)
• New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study (NCT04426539)
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ) (NCT05026177)
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) (NCT04777396)
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (NCT04777409)
• Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) (NCT05602727)
• Study of AV-1959, an Amyloid Beta Vaccine (NCT05642429)

Tucson, Ariz. 

Studies for Participants With and Without Memory Loss

• Alzheimer’s Disease Research Center (ADRC) (NCT01421420)

Studies for Participants With Memory Loss

• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ) (NCT05026177)
• Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1) (NCT06268886)

Contact Banner Alzheimer’s Institute Clinical Trials

Phoenix
901 E Willetta St.
Phoenix , AZ 85006
(602) 839-6500

Tucson
2626 E River Rd.
Tucson , AZ 85718
(520) 694-7021